Rutgers Health research has uncovered why a relatively new antibiotic for tuberculosis (TB) works against multidrug-resistant strains, potentially inspiring improved treatments and drug development strategies.

The study by scientists at Rutgers New Jersey Medical School and other institutions found that deficiencies in a critical enzyme make tuberculosis bacteria that resist old antibiotics more vulnerable to the new antibiotic bedaquiline.

Study Paper:

Catalase activity deficiency sensitizes multidrug-resistant Mycobacterium tuberculosis to the ATP synthase inhibitor bedaquiline

https://www.nature.com/articles/s41467-024-53933-8